COLL vs COP
Collegium Pharmaceutical Inc (COLL) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the COLL and COP stock pages for the full models.
Not investment advice.